Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
15. August 2023 Selskabsmeddelelse nr. 37 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager USPTO meddelelse om udstedelse af patent på behandling med...
-
15 August 2023 Announcement no. 37 Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical...
-
30 juni 2023 Meddelelse nr. 36 Status på selskabets tilgodehavende hos Portinho S.A. med betalingsfrist den 1. juli 2023 I det konsoliderede regnskab (med...
-
30 June 2023 Announcement no. 36 Status of the company's receivables from Portinho S.A. with payment deadline 1 July 2023 In the consolidated financial statement (with the...
-
15 June 2023 Announcement no. 35 Changes to the Board of Directors in Pharma Equity Group Today, the company has received notice that the Chairman of the Board of Directors, Peter Mørch Eriksen...
-
14. juni 2023 Pressemeddelelse Ny CMO i Pharma Equity Groups datterselskab Reponex Pharmaceuticals A/S Vi er glade for at kunne præsentere Dr. Christopher M Burton MD, Ph.d., (født 1973),...
-
14 June 2023 Press Release New CMO in Pharma Equity Groups subsidiary Reponex Pharmaceuticals A/S We are delighted to present Dr Christopher M Burton MD, PhD, (born 1973) an...
-
8 June 2023 Announcement no. 34 Encouraging preliminary data from the first part of a clinical study in pouchitis The safety and efficacy...
-
2 June 2023 Announcement no. 33 Inside information Settlement - purchase of shares In connection with completion of Pharma Equity Group A/S' (the "Company") purchase of Reponex...
-
May 25,2023 Announcement no. 32 Managers’ transactions Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below...